Skip to main content

FDA approves J&J's nasal spray for depression as standalone treatment

By CNBC  
   January 21, 2025

The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard treatments does little to nothing to improve depression symptoms in a patient. 

Full story


Get the latest on healthcare leadership in your inbox.